0000950170-24-003076.txt : 20240108
0000950170-24-003076.hdr.sgml : 20240108
20240108180126
ACCESSION NUMBER: 0000950170-24-003076
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240105
FILED AS OF DATE: 20240108
DATE AS OF CHANGE: 20240108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Moore Paul Andrew
CENTRAL INDEX KEY: 0001938192
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41535
FILM NUMBER: 24521288
MAIL ADDRESS:
STREET 1: 114 EAST 4TH AVENUE, SUITE 800
CITY: VANCOUVER
STATE: A1
ZIP: V5T 1G4
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zymeworks Inc.
CENTRAL INDEX KEY: 0001937653
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 108 PATRIOT DRIVE, SUITE A
CITY: MIDDLETOWN
STATE: DE
ZIP: 19709
BUSINESS PHONE: 302-274-8744
MAIL ADDRESS:
STREET 1: 108 PATRIOT DRIVE, SUITE A
CITY: MIDDLETOWN
STATE: DE
ZIP: 19709
FORMER COMPANY:
FORMER CONFORMED NAME: Zymeworks Delaware Inc.
DATE OF NAME CHANGE: 20220712
4
1
ownership.xml
4
X0508
4
2024-01-05
0001937653
Zymeworks Inc.
ZYME
0001938192
Moore Paul Andrew
C/O ZYMEWORKS INC.
108 PATRIOT DRIVE, SUITE A
MIDDLETOWN
DE
19709
false
true
false
false
Chief Scientific Officer
false
Common Stock
2024-01-05
4
M
false
17166
0.00
A
17166
D
Common Stock
2024-01-05
4
S
false
7460
10.6522
D
9706
D
Common Stock
2024-01-08
4
S
false
2339
11.2156
D
7367
D
Restricted Stock Unit
2024-01-05
4
M
false
17166
0.00
D
Common Stock
17166
34334
D
Stock Option (Right to Buy)
10.56
2024-01-05
4
A
false
90000
0.00
A
2034-01-04
Common Stock
90000
90000
D
Restricted Stock Unit
2024-01-05
4
A
false
60000
0.00
A
Common Stock
60000
60000
D
Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023.
Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.55 to $10.845, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.49 to $11.58, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on January 5, 2024.
Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
The RSUs vest in three equal annual installments beginning on January 5, 2025.
/s/ Daniel Dex, Attorney-in-Fact
2024-01-08